Janux Therapeutics Announces Proposed Public Offering
BofA Securities, TD Cowen, Stifel, Cantor and William Blair are acting as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital, BTIG and Jones are acting as co-managers for ...
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Merck gets FDA Breakthrough Therapy designation for sac-TMT
Merck (NYSE:MRK) said the FDA has granted Breakthrough Therapy designation for its antibody drug conjugate sacituzumab ...
Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients ...
Cancer Therapy Advisor8 小时
Top Lung Cancer Research of 2024
This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.
MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or ...
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
红板报 on MSN19 小时
再迎突破！复宏汉霖H药 汉斯状获批非鳞状非小细胞肺癌新适应症
2024年12月3日，上海——复宏汉霖（2696.HK）宣布，公司自主研发的创新型抗PD-1单抗H药 汉斯状（通用名：斯鲁利单抗注射液）正式获得国家药品监督管理局（NMPA）批准，联合培美曲塞和卡铂适用于表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性的不可手术切除的局部晚期或转移性非鳞状非小细胞肺癌（nsNSCLC）的一线治疗。这是H药在中国获批的第五项适应症，也是继鳞状 ...